Applying Proteomics in Clinical Trials: Assessing the Potential and Practical Limitations in Ovarian Cancer

Author： Tchabo Nana E.   Liel Meghan S.   Kohn Elise C.  

Publisher： Adis International

ISSN： 1175-2203

Source： American Journal of PharmacoGenomics, Vol.5, Iss.3, 2005-01, pp. : 141-148

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current treatment and clinical trials in ovarian cancer

By Han Liz Y   Kipps Emma   Kaye Stan B  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 4, 2010-04 ,pp. : 521-534

Informa Healthcare

Access to resources Recommend Favorite

Companies Applying Genomics and Proteomics to Cancer

By  

Pharmaceutical & Diagnostic Innovation, Vol. 1, Iss. 1, 2003-01 ,pp. : 60-63

Adis International

Access to resources Recommend Favorite

Optimising Treatment of Elderly Patients with Ovarian Cancer: Improving Their Enrolment in Clinical Trials

By Jeannine Villella  

Drugs & Aging, Vol. 22, Iss. 2, 2005-01 ,pp. : 95-100

Adis International

Access to resources Recommend Favorite

Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials?

By Dancey Janet E.  

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1728-1730

Blackwell Publishing

Access to resources Recommend Favorite

Clinical Proteomics in Cancer Research-Promises and Limitations of Current Two-Dimensional Gel Electrophoresis

By  

Current Medicinal Chemistry, Vol. 15, Iss. 23, 2008-10 ,pp. : 2393-2400

Bentham Science Publishers

Access to resources Recommend Favorite